Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96E52
UPID:
OMA1_HUMAN
Alternative names:
Metalloprotease-related protein 1; Overlapping with the m-AAA protease 1 homolog
Alternative UPACC:
Q96E52; D3DQ54; Q5T3G6; Q5T3G7; Q5T3G8; Q5T3G9; Q5T3H0; Q8NBB3
Background:
Metalloendopeptidase OMA1, mitochondrial, also known as Metalloprotease-related protein 1, plays a pivotal role in mitochondrial quality control. It is activated under stress, leading to the cleavage of proteins like OPA1, UQCC3, and DELE1, crucial for mitochondrial fusion, apoptosis, and the integrated stress response. Its interaction with cardiolipin suggests a role in regulating protein turnover.
Therapeutic significance:
Understanding the role of Metalloendopeptidase OMA1, mitochondrial could open doors to potential therapeutic strategies.